

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 46219

In re patent application of

KISO et al.

Serial No. 09/857,695

Filed: June 8, 2001

For: THERAPEUTIC AGENTS FOR HYPERAMMONEMIA

Group Art Unit: 1623

Examiner: D. Khare

RECEIVED

NOV 8 2002

TECH CENTER 1600/2900

TRANSMITTAL OF RESPONSEAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is an Response in the above-captioned application. The fee has been calculated as shown below. *(Small entity fees indicated in parentheses.)*

CLAIMS AS AMENDED						
(1)	(2)	(3)	(4)	(5)	(6)	(7)
	Claims Remaining After Amendment		Highest Number Previously Paid For	Extra Claims	Rate	Fee
Total Claims	18	-	20		18.00	0
(Small Entity)					(9.00)	
Independent claims	9	-	9		84.00	0
(Small Entity)					(42.00)	
Multiple Dependent	0	-	0	0	280.00	0
(Small Entity)					(140.00)	
Extension of Time	One Month		Two Months	Three Months		
Fee	\$110		\$400	\$920		\$920.00
(Small Entity)	(\$55)		(\$200)	(\$460)		0
Total						\$920.00


The above fees are believed to be correct. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0687 under the above Attorney Docket Number for which purpose this paper is submitted in duplicate.

Respectfully submitted,

Date: **November 6, 2002**

Paul E. White, Jr.
Reg. No. 32,011
Tel. No. 202-261-1050
Fax No. 202-887-0336

Manelli Denison & Selter, PLLC
2000 M Street, N.W.
Suite 700
Washington, D.C. 20036-3307
202.261.1000



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of
KISO, et al.

Group Art Unit: 1623

Appln. No.: 09/857,695

Examiner: D. Khare

Filed: June 8, 2001

Title: THERAPEUTIC AGENTS FOR HYPERAMMONEMIA

RECEIVED

NOV 08 2002

TECH CENTER 1600:2900

* * * * *

November 6, 2002

AMENDMENT

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

In response to the Office Action dated May 6, 2002, please amend the
subject application as follows.

IN THE CLAIMS:

Please amend claims 3, 7, 8, 9, 10, 11 and 13-18 as follows (see the
attached Appendix for the changes made to effect the below claims):

Claim 3. (Amended) The blood ammonia lowering agent according to
claim 2, wherein said xylooligosaccharide contains at least 30 wt% of xylobiose

Claim 7. (Amended) The therapeutic agent of hyperammonemia
according to claim 6, wherein said xylooligosaccharide contains at least 30 wt%
of xylobiose.